The “Super Bowl of jobs reports”
February 11, 2026
Breaking News
Image source: Pexels
The US Labor Department will publish closely watched jobs data for January on Wednesday, along with sweeping revisions to 2025 figures that could show far fewer new positions were added to the US economy than previously reported.
Private data released last week suggested the labor market remained bruising in January for out-of-work Americans, with limited job creation.
Economists surveyed by Bloomberg estimate a median gain of about 68,000 jobs in January’s report, although forecasts vary widely. The highest projection points to 135,000 new jobs, while the lowest estimate shows a loss of 10,000 roles.
The unemployment rate is expected to remain steady at 4.4%. Yahoo Finance reports.
EdgeUp
📰 Dow, S&P 500, Nasdaq futures climb as Wall Street braces for jobs report
US stock futures turned lower on Wednesday as investors waited for the long-awaited January jobs report to help set expectations for interest-rate cuts.
Contracts on the S&P 500 nudged into the red, while those on the tech-heavy Nasdaq 100 slipped 0.2% to pull back from earlier small gains.
Dow Jones Industrial Average futures held just above the flat line, coming off a third straight day of record closes. Yahoo Finance reports.
🧠 Intel stock price ticks up in premarket after 6% slide as payrolls loom
Intel’s stock ticked higher by 0.45% in premarket trading on Wednesday, recovering some ground after a steep drop the previous day.
Shares changed hands at $47.34 ahead of the opening bell, following Tuesday’s close at $47.13, down 6.19%.
This shift is significant, as Intel is once again behaving like a high-beta chip play.
The stock’s decline on Tuesday dropped it straight into a broader shakeout across AI-infrastructure names, companies that supply hardware for artificial intelligence.
During the selloff, Western Digital, Seagate, Micron, Lam Research and KLA all ranked among the session’s notable losers. TechStock² reports.
🧪 Quince Therapeutics stock price jumps in premarket as strategic review keeps deal talk alive
Quince Therapeutics jumped roughly 48% to 78 cents in premarket action Wednesday, building on a steep rally that followed news the company brought in an adviser to weigh strategic alternatives.
This is significant, “strategic alternatives” usually hints at a possible sale, merger, licensing arrangement, or some other deal that could change prospects in a flash.
With penny stocks, even minor changes in sentiment can spark outsized percentage moves. TechStock² reports.
💼 The sell-off in AI losers has been so steep that this famed activist investor has reportedly sprung into action
A report published by Barclays on Wednesday described how AI disruption is driving extreme stock dispersion.
Companies seen as being on the losing side of AI trends have suffered sharp valuation cuts and are now considered tactically oversold.
Barclays said this is creating selective opportunities across software, media and internet, and business services sectors.
The same view appears to be shared by Elliott Management. The Financial Times reported that the activist investor has bought an undisclosed stake in the London Stock Exchange Group.
Although neither party has confirmed the report, shares in the London Stock Exchange Group jumped about 8% at the open in London on Wednesday, before easing back to trade around 2.5% higher at £75.60. MarketWatch reports.
🧴 NKTR stock skyrockets: Wall Street sees up to 200% upside as skin trial crushes even bull case forecasts
Nektar Therapeutics reported that complete skin clearance rates increased twofold to fivefold during the maintenance phase of its trial.
Shares of Nektar Therapeutics (NKTR) logged their strongest session in 19 months on Tuesday after Wall Street analysts lifted price targets and pointed to triple-digit upside following “robust” results from the company’s atopic dermatitis trial.
NKTR stock surged 51% on Tuesday to hit $56 and jumped another 5% in after-hours trading. StockTwits reports.
🧸 Mattel shares drop 28% after toy maker’s holiday sales sputter
The toy maker’s anticipated holiday surge came up short, leading it to post sales and profit below Wall Street expectations in the fourth quarter.
Mattel shares plunged as much as 28% in late trading after the toy maker said an anticipated surge in holiday sales came up short, and it issued a lower than expected profit forecast for 2026. Yahoo Finance reports.
Top 5 Movers in Early Pre-Market
(All pricing and percent gains are based on Early Pre-Market from 4:00 AM to 7:00 AM Eastern Time)
Stock Analysis reports.
1) MNTN: MNTN, Inc.
Total gain: +35.42%
2) BNRG: Brenmiller Energy Ltd
Total gain: +33.74%
3) ELAB: PMGC Holdings Inc.
Total gain: +33.33%
4) STIM: Neuronetics, Inc.
Total gain: +27.40%
5) BETA: BETA Technologies, Inc.
Total gain: +21.71%
Yesterday’s Biggest Movers
The closing price of the top three market percent gainers trading near or above $3 on February 10.
Stock Analysis reports.
*All pricing and percent gains are based on regular market trading hours from 9:30am to 4:00pm Eastern Time
1) EVMN: Evommune, Inc.
Total gain: +70.87%
The company announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301.
This long-acting fusion protein consisting of an interleukin-18 (IL-18) binding protein and an anti-serum albumin Fab-associated domain, achieved highly statistically significant outcomes in adult patients with moderate-to-severe atopic dermatitis (AD).
The 70-patient trial was designed to evaluate the safety and efficacy of intravenous dosing of 5mg/kg on day 1 and day 28 (n=48 active, n=22 placebo) over 12 weeks. Businesswire reports.
2) NKTR: Nektar Therapeutics
Total gain: +51.07%
The company announced that it has commenced an underwritten public offering of $300,000,000 of its shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.
All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Nektar. In addition, Nektar intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock at the public offering price per share, less underwriting discounts and commissions.
The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. PR Newswire reports.
3) PHGE: BiomX Inc.
Total gain: +44.37%
The stock appeared to be moving on no notable news.
Today’s Notable Earnings
*Estimate and Actual numbers represent Earnings Per Share in US Dollars
DAO: Youdao
Q4 2025
Before Market Open
Estimate: N/A
Actual: 0.070
NTES: NetEase
Q4 2025
Before Market Open
Estimate: 1.850
Actual: 1.570
ADRNY: Koninklijke Ahold Delhaiz
Q4 2025
Before Market Open
Estimate: N/A
Actual: 0.850
Today’s Economic Dates
Time (ET) / Report / Period
8:30 AM - U.S. employment report - Jan.
8:30 AM - U.S. unemployment rate - Jan.
8:30 AM - U.S. hourly wages - Jan.
Parting Thoughts
“The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.”
– Li Lu
Sourced in: Li Lu Quotes – AZQuotes.
Disclaimer
TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas ; TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF); and TradeZero Europe B.V., a Dutch broker dealer, authorized and regulated by the Dutch Authority for the Financial Markets (AFM) (collectively, the “TradeZero Broker Dealers”).
TradeZero Broker Dealers offer self-directed electronic securities trading to their customers. TradeZero Broker Dealers do not provide financial or trading advice and do not make investment recommendations to their customers. This communication does not constitute an offer to sell or a solicitation to buy any security or instrument which it may reference. There is a risk of loss in online trading of securities including equities and options. Trading on margin is for experienced investors whereby the loss can be greater than your initial investment. Likewise, short selling as a securities trading strategy is extremely risky and can lead to potentially unlimited losses. Options trading is not suitable for all investors as it can involve risk that may expose investors to significant losses. Please read the Characteristics and Risks of Standardized Options, also known as the Options Disclosure Document (ODD) at OCC.
If you have any specific questions about TradeZero's brokerage services, please reach out to the TradeZero Broker Dealer servicing your jurisdiction.